For instance, research in pancreatic cancer demonstrates that the coadministration of HDAC inhibitors and gemcitabine enhances SLC29A1 and DCK gene expression, which are integral to gemcitabine transport and activation [30]. This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.